Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients

Inclusion Criteria: * the subject must have participated in previous Lamazym-trials: phase 2b: 2011-004355-40 or phase 3: 2012-000979-17 * Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trial-related activities * The subject and his/her guardian(s) must have the ability to comply with the protocol Exclusion Criteria: * Presence of known clinically significant cardiovascular, hepatic, pulmonary, or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial * Any other medical condition or serious intercurrent illness, or extenuating circumstances that, in the opinion of the Investigator, would preclude participation in the trial * Pregnancy. Pregnant woman is excluded. Before start fot he treatment the investigators will for women of childbearing potential perform a pregnancy test and decide whether or not there is a need for contraception * Psychosis; any psychotic disease, also in remission, is an exclusion criteria * Planned major surgery that, in the opinion of the Investigator, would preclude participation in the trial * Adult patients who, in the opinion of the Investigator, would be unable to give consent, and who does not have any legal protection or guardianship * total IgE \> 800 IU/mL * Known allergy to the IMP or any excipients (Sodium-Phosphate, Glycine, Mannitol)